Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Breast Cancer Res Treat ; 182(2): 389-399, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32495001

ABSTRACT

PURPOSE: There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case-control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. METHODS: Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. RESULTS: 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). CONCLUSIONS: We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients.


Subject(s)
Administration, Metronomic , Antineoplastic Agents/administration & dosage , Breast Neoplasms/therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Case-Control Studies , Chemotherapy, Adjuvant/methods , Cyclophosphamide/administration & dosage , Dose-Response Relationship, Drug , Female , Humans , Kaplan-Meier Estimate , Mastectomy , Methotrexate/administration & dosage , Middle Aged , Neoadjuvant Therapy/methods , Progression-Free Survival , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective Studies
2.
Eur J Surg Oncol ; 38(2): 118-24, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22152942

ABSTRACT

BACKGROUND: In recent years, surgeons have utilized Harmonic instruments to perform breast cancer resection. Retrospective and prospective studies have demonstrated that the use of this surgical device for mastectomy and axillary dissection can reduce perioperative blood loss, seroma formation, and duration and total amount of drainage. No study has analyzed the feasibility of Harmonic instruments in breast-conserving surgery. We conducted a prospective, randomized clinical trial comparing Harmonic instrument and conventional surgery in the performance of breast-conserving surgery and axillary procedures to determine differences in surgical procedures, postoperative outcome, and complications. METHODS: One hundred and six patients with operable breast cancer who underwent breast-conserving surgery at a single institution between December 2009 and January 2011 were included in the analysis. Surgery was performed in 52 patients with the Harmonic Focus(®) device and in 54 with scissors and electrocautery. This study focused on operative time, drainage volume, and postoperative outcome measures like blood loss, surgery related complications and patient-reported postoperative pain. RESULTS: We found a multivariable independent influence in axillary seroma formation and volume of breast drainage with HS. Evident difference in volume and duration of axillary and breast drainage, subjective and objective postoperative pain, reduction in serum hemoglobin, size and weight of resected breast tissue and length of hospital stay in favor of the Harmonic instrument could also be shown. DISCUSSION: The Harmonic instrument provides key benefits in surgical technique, postoperative outcome, and complication rates in breast cancer surgery.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Segmental/instrumentation , Neoplasm Recurrence, Local/pathology , Surgical Instruments , Ultrasonic Therapy/instrumentation , Academic Medical Centers , Adult , Aged , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Chi-Square Distribution , Female , Follow-Up Studies , Germany , Humans , Logistic Models , Mastectomy, Segmental/methods , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness/pathology , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Postoperative Care/methods , Postoperative Complications/physiopathology , Prospective Studies , Risk Assessment , Seroma/etiology , Seroma/therapy , Statistics, Nonparametric , Survival Analysis , Treatment Outcome , Ultrasonic Therapy/methods
3.
Eur J Cancer Care (Engl) ; 18(5): 500-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19490009

ABSTRACT

About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patients' quality of life. Prevalence and severity of symptoms were not influenced by length of tamoxifen treatment. Patients were damaged in their constitution in respect to previous chemotherapy and pre-existing diseases; no influence was found by age or histopathological tumour characteristics. Our survey determines that breast cancer patients experience significant influence on quality of life by the negative impact on the physical, emotional and social functioning caused by tamoxifen treatment. Explicit attention to changes in quality of life should be considered as part of the standard care for women receiving adjuvant tamoxifen treatment.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Breast Neoplasms/psychology , Quality of Life/psychology , Tamoxifen/adverse effects , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Body Image , Breast Neoplasms/drug therapy , Breast Neoplasms/epidemiology , Chemotherapy, Adjuvant/adverse effects , Chemotherapy, Adjuvant/methods , Female , Humans , Middle Aged , Surveys and Questionnaires , Tamoxifen/therapeutic use
4.
Ann Oncol ; 20(2): 258-64, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18824499

ABSTRACT

BACKGROUND: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. PATIENTS AND METHODS: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age <35 years, (ii) grade 3, (iii) human epithelial growth factor receptor-2 positivity, (iv) vascular invasion, (v) progesterone receptor negativity, (vi) grade 2 tumors >2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). RESULTS: The Node-Negative-Breast Cancer-3 (NNBC-3) algorithm enlarged the low-risk group to 37% as compared with Adjuvant! (17%) and St Gallen (18%), respectively. In multivariate analysis, both Adjuvant! [P = 0.027, hazard ratio (HR) 3.81, 96% confidence interval (CI) 1.16-12.47] and the NNBC-3 risk classification (P = 0.049, HR 1.95, 95% CI 1.00-3.81) significantly predicted OS, but only the NNBC-3 algorithm retained its prognostic significance in multivariate analysis for DFS (P < 0.0005). CONCLUSION: The novel NNBC-3 risk algorithm is the only clinicopathological risk classification algorithm significantly predicting DFS as well as OS.


Subject(s)
Algorithms , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Genes, erbB-2 , Neovascularization, Pathologic , Adult , Aged , Aged, 80 and over , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Longitudinal Studies , Middle Aged , Multivariate Analysis , Neoplasm Staging , Predictive Value of Tests , Prognosis , Prospective Studies , Receptors, Progesterone/analysis , Regression Analysis , Retrospective Studies , Risk Assessment , Sensitivity and Specificity , Survival Analysis , Time Factors , Treatment Outcome
5.
Int J Biol Markers ; 19(3): 236-9, 2004.
Article in English | MEDLINE | ID: mdl-15503826

ABSTRACT

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 serum levels in patients with breast cancer, DCIS I-III or benign breast lesions and in healthy women were 48.8 (18-82.4) pg/mL, 45.3 (26.9-58.3) pg/mL, 47.2 (17.2-80.5) pg/mL and 51.6 (30.9-65.1) pg/mL, respectively (p=0.2). In breast cancer patients TGF-beta1 serum levels showed no statistically significant correlation with tumor stage, lymph node involvement, histological grade, estrogen receptor status and progesterone receptor status. Our data fail to indicate any correlation between serum TGF-beta1 levels and clinicopathological parameters of breast diseases. Serum TGF-beta1 levels do not provide clinical information in addition to established tumor markers.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/pathology , Transforming Growth Factor beta/blood , Adult , Aged , Aged, 80 and over , Humans , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Transforming Growth Factor beta1
8.
Geburtshilfe Frauenheilkd ; 55(3): 167-70, 1995 Mar.
Article in German | MEDLINE | ID: mdl-7665066

ABSTRACT

In a double-blind, randomised study we treated 36 women in the puerperium with haemoglobin concentration below 9 g/dl with 400 mg Fe . 20 women received 20,000 IE erythropoietin (rHuEPO) i.v. in addition, 12 women received placebos. In both groups there were no differences in the haematological and iron parameters in the first 4 weeks after delivery. The results show that the additional therapy with rHuEPO in postpartum anaemia is not justified. The limiting factor in a quick correction of the postpartum anaemia is the insufficient presence of iron at the end of pregnancy. The therapy of choice for quick and safe correction of p.p. anaemia is the effective intravenous iron supplementation.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Erythropoietin/administration & dosage , Iron/administration & dosage , Puerperal Disorders/drug therapy , Anemia, Iron-Deficiency/blood , Combined Modality Therapy , Double-Blind Method , Erythrocyte Count/drug effects , Erythropoietin/adverse effects , Female , Ferritins/metabolism , Hematocrit , Hemoglobinometry , Humans , Infusions, Intravenous , Prospective Studies , Puerperal Disorders/blood , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...